D&D Pharmatech to acquire 10.9% of Z-Alpha Holdings for ₩10.0bn
D&D Pharmatech Inc. filed to acquire 4,299,965 shares of Z-Alpha Holdings, Inc. (USA) for ₩10.0bn, equal to 10.9% of its equity. After the acquisition, the company's stake would be 4.8%, with the deal expected on Nov 16, 2026.
Key facts
| Target company | Z-Alpha Holdings, Inc. (USA) |
|---|---|
| Shares | 4,299,965 shares |
| Deal amount | ₩10.0bn |
| % of equity | 10.9% |
| Stake after | 4.8% |
| Purpose | Strengthening influence by participating in fundraising for a US alpha radiopharmaceutical therapy developer |
| Expected date | Nov 16, 2026 |
Comparison
| Amount as % of prior-year revenue (calculated) | 233.3% |
|---|---|
| Revenue 2025 | ₩4.3bn |
| Revenue 2024 | ₩11.4bn |
Context
The filing gives the purpose as strengthening influence by participating in fundraising for a US alpha radiopharmaceutical therapy developer. By our calculation, the ₩10.0bn deal amount is 233.3% of prior-year revenue, and FY2025 revenue was ₩4.3bn.
Source: DART (Financial Supervisory Service) · Original filing on DART ↗